PRIMARY STUDY
Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder
Key Findings: This mouse model of long-term use of CBD oil in Autism Spectrum Disorder (ASD) found a reduction of symptoms of anxiety and repetitive behaviors as well as a link to the mechanism of action within the CB1 receptors, glutamate, and alterations of RNA neurotransmission genes in the treatment group.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Israel
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Endocannabinoid (unspecified)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype I, Chemotype III
Receptors Studied: CB1
Ligands Studied: GABA, Glutamate
Sub-Ratio: THC:CBD 1:25 THC:CBD 1:0
Dosage: CBD:THC (25 mg/kg:1 mg/kg) and THC (1 mg/kg)
Route of Administration: Oral (Ingestion)
Citation: Poleg S, et al. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. Transl Psychiatry. 2021; 11:524. doi: 10.1038/s41398-021-01612-3
Authors: Poleg S, Kourieh E, Ruban A, Shapira G, Shomron N, Barak B, Offen D
